TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1734903

Group type: EXPERIMENTAL
Intervention: Ice chips
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cold air
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Short-wave diathermy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ligno-paraffin
Number of subjects: 42
Study: 6426846

Group type: EXPERIMENTAL
Intervention: L-carnitine administration (20 and 25 mg/kg body weight)
Number of subjects: 4
Study: 31222496

Group type: EXPERIMENTAL
Intervention: Reinforced POSE 18-plication
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard POSE method
Number of subjects: 15
Study: 29805981

Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 27823695

Group type: EXPERIMENTAL
Intervention: Remote ischemic per-postconditioning (RIperpostC)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 93
Study: 25015176

Group type: EXPERIMENTAL
Intervention: UMEC/VI 125/25 mcg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: UMEC 125 mcg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22608375

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and counseling for smoking cessation
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Matched community-dwelling smokers
Number of subjects: 1346

Group type: COMPARATOR
Intervention: Trial participants who continued smoking
Number of subjects: 1346
Study: 20813531

Group type: EXPERIMENTAL
Intervention: New upper extremity sparing non-weight bearing orthosis
Number of subjects: 10
Study: 17209669

Group type: COMPARATOR
Intervention: Limaprost 30 microg/day
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Limaprost 15 microg/day
Number of subjects: 282
Study: 15309457

Group type: EXPERIMENTAL
Intervention: Perilla extract (PE) containing 200 mg rosmarinic acid (RA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 11886692

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 148
Study: 9821422

Group type: EXPERIMENTAL
Intervention: Early feeding (initiation at 4 days of age)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Standard feeding (initiation at 15 days of age)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Milk feeding
Number of subjects: 135

Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Lactase activity
Number of subjects: 135
Study: 7653809

Group type: EXPERIMENTAL
Intervention: Intermittent bolus injections of propofol (10 mg) after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Conventional syringe infusion pump (25-100 micrograms.kg-1.min-1) after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Target-controlled infusion (TCI) device with initial target concentration of 2 micrograms/mL adjusted between 1 and 4 micrograms/mL after an initial IV bolus of 0.3 mg/kg
Number of subjects: 63
Study: 2173391

Group type: EXPERIMENTAL
Intervention: Dronabinol, 10 mg plus placebo q.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prochlorperazine, 10 mg plus placebo q.i.d.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dronabinol plus prochlorperazine, each 10 mg q.i.d.
Number of subjects: 19
Study: 76794

Group type: EXPERIMENTAL
Intervention: Home management group
Number of subjects: 349

Group type: COMPARATOR
Intervention: Hospital management group
Number of subjects: 349
Study: 29886146

Group type: EXPERIMENTAL
Intervention: ARCT group
Number of subjects: 255

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study: 28732773

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP (tenofovir monotherapy or combination of tenofovir and emtricitabine)
Number of subjects: 1470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1470
Study: 24875466

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) starting on the first postoperative day
Number of subjects: 109

Group type: COMPARATOR
Intervention: Late oral feeding (LOF) remaining nil by mouth until the return of bowel sounds
Number of subjects: 109
Study: 23557249

Group type: EXPERIMENTAL
Intervention: Telephone care management intervention
Number of subjects: 5074

Group type: COMPARATOR
Intervention: Fee-for-service system without care management services
Number of subjects: 5074
Study: 21570517

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH)
Number of subjects: 7761

Group type: COMPARATOR
Intervention: Standard care without LVH
Number of subjects: 7761

Group type: EXPERIMENTAL
Intervention: Degree of quantitative ST depression (STD) among LVH patients
Number of subjects: 7761

Group type: EXPERIMENTAL
Intervention: Electrocardiographic-determined LVH
Number of subjects: 7761

Group type: EXPERIMENTAL
Intervention: ST depression (STD)
Number of subjects: 7761
Study: 19261545

Group type: EXPERIMENTAL
Intervention: Expert Patient Programme (EPP)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control Group (wait-list for EPP)
Number of subjects: 192
Study: 17112855

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 2 x 600 mg/d for 3 months (GI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (GII) not receiving PTX
Number of subjects: 22
Study: 15701267

Group type: EXPERIMENTAL
Intervention: 1α-hydroxy-24-ethyl-cholecalciferol (vitamin D5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11376256

Group type: EXPERIMENTAL
Intervention: 24 hour two dose of 225 mL dilute contrast material
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 24 hour five dose of 225 mL dilute contrast material
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 48 hour four dose of 225 mL dilute contrast material
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 48 hour six dose of 225 mL dilute contrast material
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 48 hour seven dose of 225 mL dilute contrast material
Number of subjects: 56
Study: 8985215

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 3
Study: 8215474

Group type: EXPERIMENTAL
Intervention: Idarubicin + Cytarabine (IDA + Ara-C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Daunorubicin + Cytarabine (DNR + Ara-C)
Number of subjects: 32
Study: 3566389

Group type: EXPERIMENTAL
Intervention: Multidose cold high potassium cardioplegia (27 mEq of KCl/L)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Initial cold high potassium (27 mEq/L) cardioplegia followed by boluses of cold low potassium (7 mEq of KCl/L) solution
Number of subjects: 56
Study: 28281936

Group type: EXPERIMENTAL
Intervention: Combat exposure (violent combat)
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Combat exposure (proximity to wounding or death)
Number of subjects: 2510

Group type: EXPERIMENTAL
Intervention: Combat exposure (explosive device exposure)
Number of subjects: 2510
Study: 27327779

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention augmented by text messaging
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 23788510

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=24)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Attention control (n=19)
Number of subjects: 43
Study: 22751086

Group type: EXPERIMENTAL
Intervention: Rivastigmine (3-4.5 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19943060

Group type: EXPERIMENTAL
Intervention: Cold pressor test (4 degrees C water for 2 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isometric handgrip exercise (30% maximal voluntary contraction for 2 min)
Number of subjects: 23
Study: 18662829

Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: 1 mg intravitreal triamcinolone
Number of subjects: 693

Group type: COMPARATOR
Intervention: focal/grid photocoagulation
Number of subjects: 693
Study: 15945136

Group type: EXPERIMENTAL
Intervention: Dietary supplements usage
Number of subjects: 494

Group type: COMPARATOR
Intervention: Non-metropolitan oldest-old
Number of subjects: 494

Group type: COMPARATOR
Intervention: Metropolitan oldest-old
Number of subjects: 494

Group type: COMPARATOR
Intervention: Metropolitan young-olds
Number of subjects: 494
Study: 11844632

Group type: EXPERIMENTAL
Intervention: Single-dose oral tramadol (75 mg or 112.5 mg) plus acetaminophen (650 mg or 975 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination analgesics (tramadol plus acetaminophen)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Components alone (tramadol or acetaminophen)
Number of subjects: 7
Study: 10338052

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infiltrated into the harvest site
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control site (no bupivacaine)
Number of subjects: 24
Study: 8522642

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for 6 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (three times daily for 6 days)
Number of subjects: 12
Study: 1781415

Group type: EXPERIMENTAL
Intervention: Zileuton (200 mg to 800 mg)
Number of subjects: 0
Study: 6996930

Group type: EXPERIMENTAL
Intervention: 20 mg clobazam (single daily dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 5 mg diazepam (3-times daily)
Number of subjects: 45
Study: 31864126

Group type: EXPERIMENTAL
Intervention: Life skills education program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo education program
Number of subjects: 0
Study: 30944685

Group type: EXPERIMENTAL
Intervention: Raw viscosity group (RV, n=58)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low viscosity group (LV, n=60)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 118
Study: 28188268

Group type: EXPERIMENTAL
Intervention: GUIDED-HF strategy (tailored discharge plan, home visit, outpatient follow-up, coaching calls)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard ED discharge
Number of subjects: 700
Study: 26235604

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (43.2 Gy to the whole breast in 18 fractions for 24 days with a concomitant boost of 50.4 Gy to the tumor bed)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard radiotherapy (45 Gy to the whole breast in 25 fractions for 44 days with a boost to the tumor bed of 59 Gy)
Number of subjects: 80
Study: 23661337

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study: 21587324

Group type: EXPERIMENTAL
Intervention: SICS with sutureless trabeculectomy (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SICS with trabeculectomy using W-shaped incision (Group B)
Number of subjects: 30
Study: 19776297

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention during rounds with nephrology unit team
Number of subjects: 600

Group type: COMPARATOR
Intervention: Preintervention phase (control)
Number of subjects: 600
Study: 17356445

Group type: EXPERIMENTAL
Intervention: Co-bedding
Number of subjects: 0
Study: 15835412

Group type: EXPERIMENTAL
Intervention: Needle bevel facing upwards
Number of subjects: 48

Group type: COMPARATOR
Intervention: Needle bevel facing downwards
Number of subjects: 48
Study: 11177119

Group type: EXPERIMENTAL
Intervention: Methyltestosterone (MT) 40 mg/d for 3 days, then 240 mg/d for 3 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9394322

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS) at 4 mg/kg as a predialysis intravenous bolus followed by continuous infusion of 0.65 mg/kg/h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dermatan sulphate (DS)
Number of subjects: 10
Study: 8182901

Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) given orally or intravenously
Number of subjects: 6
Study: 3358169

Group type: EXPERIMENTAL
Intervention: Intravenous glucagon
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study: 28337949

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Masters‐Johnson sex therapy (MJST)
Number of subjects: 0
Study: 28959461

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 101
Study: 26194791

Group type: EXPERIMENTAL
Intervention: Op Volle Kracht (OVK) plus Treatment as Usual (TAU)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 182
Study: 23895814

Group type: EXPERIMENTAL
Intervention: Persistent patients
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Nonpersistent patients
Number of subjects: 25620
Study: 20356942

Group type: EXPERIMENTAL
Intervention: Mammographic screening (Two-County Trial)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Mammographic screening (UK Breast Screening Programme)
Number of subjects: 1000
Study: 18437408

Group type: EXPERIMENTAL
Intervention: Cineole
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (combination of five different components)
Number of subjects: 150
Study: 16767615

Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Homemade sports drink
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diluted orange juice
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sports drink and diluted orange juice
Number of subjects: 50
Study: 14565783

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (acetylsalicylic acid) therapy
Number of subjects: 15000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15000
Study: 10958177

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Prednisolone (PSL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glandular symptoms (G)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Extraglandular symptoms (EG)
Number of subjects: 15
Study: 8840054

Group type: EXPERIMENTAL
Intervention: Combined general and epidural anaesthesia with postoperative epidural analgesia (EPI)
Number of subjects: 99

Group type: COMPARATOR
Intervention: General anaesthesia followed by postoperative intravenous analgesia (GA)
Number of subjects: 99
Study: 1465583

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CF)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Tobramycin/Cefuroxime (T/C)
Number of subjects: 310
Study: 6368777

Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 91

Group type: COMPARATOR
Intervention: Ampicillin or Chloramphenicol
Number of subjects: 91
Study: 31304862

Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter Defibrillator (ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study: 30439675

Group type: EXPERIMENTAL
Intervention: Positivity-approach training (4 sessions)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sham training (4 sessions)
Number of subjects: 240
Study: 27810633

Group type: EXPERIMENTAL
Intervention: Smartphone-based education app
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lecture-based education (Control)
Number of subjects: 73
Study: 25759568

Group type: EXPERIMENTAL
Intervention: MP‐BV (inertial sensor combined with BioVal software)
Number of subjects: 77
Study: 22704860

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 21881326

Group type: EXPERIMENTAL
Intervention: Intracardiac transplantation of unselected autologous bone marrow cells (BMC)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CABG concomitant with BMC-TX
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CABG only)
Number of subjects: 22
Study: 18782657

Group type: EXPERIMENTAL
Intervention: GMCSF
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 59
Study: 17267529

Group type: EXPERIMENTAL
Intervention: Case-Based Learning (CBL)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Human Patient Simulation (HPS)
Number of subjects: 102
Study: 15111373

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/d
Number of subjects: 619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study: 11434938

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 64

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 64
Study: 9766413

Group type: EXPERIMENTAL
Intervention: Highest intensity of after care services
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Long-term home visiting services
Number of subjects: 81

Group type: COMPARATOR
Intervention: After care services (various groups)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Early discharge with any after care system
Number of subjects: 81
Study: 8153939

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 1000 micrograms twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Prednisone 10 mg once daily
Number of subjects: 17
Study: 3203661

Group type: EXPERIMENTAL
Intervention: Dynamic exercise (leg extension exercise) at 50 times/min for 1 min with weights lifted through three different distances.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Static exercise (holding weights without movement) at 50% maximal voluntary contraction (MVC) for 1 min.
Number of subjects: 5
Study: 30819217

Group type: EXPERIMENTAL
Intervention: Gift card incentive group
Number of subjects: 2426

Group type: EXPERIMENTAL
Intervention: Charity donation incentive group
Number of subjects: 2426

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 2426
Study: 28825570

Group type: EXPERIMENTAL
Intervention: pdC1‐INH
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: icatibant
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: both pdC1‐INH and icatibant
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: self-injection
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: home treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: early treatment decision
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: full coverage
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: no coverage
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: partial reimbursement
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: sharing treatment dose
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: access to medication
Number of subjects: 225
Study: 26214772

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 via four weekly intravenous drip)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vincristine (0.02 mg/kg by intravenous drip once a week for three months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vincristine
Number of subjects: 50
Study: 24007767

Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling intervention
Number of subjects: 211

Group type: COMPARATOR
Intervention: Telephone reminder and barriers assessment, followed by a mailed home tailored barriers print brochure
Number of subjects: 211

Group type: COMPARATOR
Intervention: Enhanced standard care comprising telephone reminder and barriers assessment
Number of subjects: 211
Study: 21261975

Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) initiated within 24-48 hours after ICU admission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late parenteral nutrition (PN) initiated on day 8 when caloric target is not reached
Number of subjects: 0
Study: 18581100

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16514301

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (300/100 mg) QD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (400/100 mg) BID
Number of subjects: 0
Study: 14641992

Group type: COMPARATOR
Intervention: Standard postoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant or alternative chemotherapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor/tyrosine kinase inhibitor gefitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of new approaches and standard therapy
Number of subjects: 0
Study: 10837389

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB) therapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) therapy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 85
Study: 9428991

Group type: EXPERIMENTAL
Intervention: Active warm up (AWU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive warm up (PWU)
Number of subjects: 0
Study: 8451470

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam-Propofol combination
Number of subjects: 90
Study: 2934124

Group type: EXPERIMENTAL
Intervention: FAM (5‐fluorouracil, Adriamycin [doxorubicin], mitomycin)
Number of subjects: 196

Group type: COMPARATOR
Intervention: FSM (5‐fluorouracil, streptozotocin, mitomycin)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 196

Group type: COMPARATOR
Intervention: FSM
Number of subjects: 196
Study: 30080869

Group type: EXPERIMENTAL
Intervention: Reported last menstrual period
Number of subjects: 4390

Group type: EXPERIMENTAL
Intervention: Symphysis-fundal height measurement
Number of subjects: 4390

Group type: EXPERIMENTAL
Intervention: New Ballard Score
Number of subjects: 4390

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4390